On the other hand, the NRF2-driven overexpression of aldo keto reductase 1C (AKR1C1) enzymes has been associated with therapy resistance in T-cell acute lymphoblastic leukemia (T-ALL) and their genetic or pharmacologic inhibition to enhance the efficacy of vincristine treatment [164]. The gene discussed is NFE2L2; the disease is acute lymphoblastic leukemia.